Exploring New paradigms for Health

R&D

Dr Shaidah Asmall

October 2007

Product Development

To global physical, mental and social well-being

Absence of Solutions

Validity of Assumptions • Pharma innovate drugs for developed countries

– Rate of Innovation decreasing Correa

• Appropriate profit motive will lead to innovation– IAVI one of first vaccine development initiatives– At present more than 80 in development– Big pharma actively involved in vaccine development– However limited success

• Lack of ability to pay– 20 years Chinese economy larger than USA – although % of poor will be large – today 700m below $2 day– Indian economy also expanding– Cover about a third of world population

Future Scenarios

• Biotech and Nanotech “revolution”– Rate of new developments in health are

increasing– However, majority at the conceptual stage– Known targets but looking for new

entities/delivery vehicles

• Shorter Cycle “mind to market”– IT cycle is about 15 months– Biotech cycle is about 30 months

Possible interventionsin value chain

• Prizes for ideas

• Funding for development– Patent pool;

• CAMC for commercialisation

Acknowledgements